Economic Burden Associated with Major Surgery in Patients with von Willebrand Disease: A United States Retrospective Administrative Database Analysis

References

• Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080. doi:10.1056/NEJMra1601561
   PubMed Web of Science ®Google Scholar
• Sadler JE, Budde U, Eikenboom JC, et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. doi:10.1111/j.1538-7836.2006.02146.x
   PubMed Web of Science ®Google Scholar
• Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232. doi:10.1111/j.1365-2516.2007.01643.x
   PubMed Web of Science ®Google Scholar
• Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis. 2014;25(3):206–216. doi:10.1097/MBC.0000000000000065
   PubMed Web of Science ®Google Scholar
• Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost. 2010;8(1):213–216. doi:10.1111/j.1538-7836.2009.03661.x
   PubMed Web of Science ®Google Scholar
• Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR. Von Willebrand disease in the United States: a perspective from Wisconsin. Semin Thromb Hemost. 2011;37(5):528–534. doi:10.1055/s-0031-1281039
   Web of Science ®Google Scholar
• Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160–174. doi:10.1055/s-0037-1613992
   PubMed Web of Science ®Google Scholar
• Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893–898. doi:10.1016/S0022-3476(05)80384-1
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E. Evolution of replacement therapy for von Willebrand disease: from plasma fraction to recombinant von Willebrand factor. Blood Rev. 2019;38:100572. doi:10.1016/j.blre.2019.04.001
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Rev Hematol. 2016;9(9):825–830. doi:10.1080/17474086.2016.1214070
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mamaev A, Wang J-D, et al. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery. J Thromb Haemost. 2019;17(1):52–62. doi:10.1111/jth.14313
   PubMed Web of Science ®Google Scholar
• Windyga J, Dolan G, Altisent C, Katsarou O, López Fernández MF, Zülfikar B; EHTSB. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. Haemophilia. 2016;22(5):739–751. doi:10.1111/hae.12955
   PubMed Web of Science ®Google Scholar
• Berntorp E. Replacement therapy during surgery in von Willebrand disease needs personalization. Haemophilia. 2018;24(3):338–340. doi:10.1111/hae.13488
   Web of Science ®Google Scholar
• Hazendonk HCAM, Heijdra JM, de Jager NCB, et al; “OPTI-CLOT” and “WIN” study group. Analysis of current perioperative management with Haemate® P/Humate P® in von Willebrand disease: identifying the need for personalized treatment. Haemophilia. 2018;24(3):460–470. doi:10.1111/hae.13451
   Web of Science ®Google Scholar
• Smilowitz NR, Gupta N, Guo Y, Bangalore S, Berger JS. Perioperative bleeding and thrombotic risks in patients with von Willebrand disease. J Thromb Thrombolysis. 2017;44(1):67–70. doi:10.1007/s11239-017-1504-2
   Web of Science ®Google Scholar
• Kulaylat AS, Schaefer EW, Messaris E, Hollenbeak CS. Truven Health Analytics MarketScan databases for clinical research in colon and rectal surgery. Clin Colon Rectal Surg. 2019;32(1):54–60. doi:10.1055/s-0038-1673354
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Lu M, Oladapo A, Wu Y, Farabakhshian S, Ewenstein B. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. J Manag Care Spec Pharm. 2021;27(2):175–185. doi:10.18553/jmcp.2020.20327
   PubMed Web of Science ®Google Scholar
• Holm E, Carlsson KS, Lövdahl S, Lail AE, Abshire TC, Berntorp E. Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network. Haemophilia. 2018;24(4):628–633. doi:10.1111/hae.13473
   PubMed Web of Science ®Google Scholar
• Abshire TC, Federici AB, Alvárez MT, et al. Prophylaxis in severe forms of von Willebrand’s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia. 2013;19(1):76–81. doi:10.1111/j.1365-2516.2012.02916.x
   PubMed Web of Science ®Google Scholar
• Abshire T, Cox-Gill J, Kempton CL, et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network. J Thromb Haemost. 2015;13(9):1585–1589. doi:10.1111/jth.12995
   PubMed Web of Science ®Google Scholar
• Holm E, Abshire TC, Bowen J, et al. Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network. Blood Coagul Fibrinolysis. 2015;26(4):383–388. doi:10.1097/MBC.0000000000000257
   PubMed Web of Science ®Google Scholar
• Sidonio RF, Haley KM, Fallaize D. Impact of diagnosis of von Willebrand disease on patient outcomes: analysis of medical insurance claims data. Haemophilia. 2017;23(5):743–749. doi:10.1111/hae.13292
   PubMed Web of Science ®Google Scholar